Member Info for Dandanman

We need more of a shot in the arm than Lateral Flow Testing!!

Following Up Up comments re future for this unliked by the City share the latest figures and market reaction suggests the figures were better than expected. The founder shareholder issues are the main drag on share price performance . Can’t expect the outcome of succession strategy to be a happy one for all interested parties in light of investor and institutional short termism and the company segments being worth more than the whole.

Suggestions on a post card please or should it be in an email!

The RNS suggests 10 months of trials/assessments so 2025 before a result . Is this gap being funded by our new Ewing family buddies??!!

I also had shares in VRS and commented at an AGM that Directa seemed to be better organised and funded albeit via EU. Both have cost me even though graphene still seems a wonder material which no one wants to pay for. So many patents but are they any value? Is it unreasonable to be thinking cut your losses as I have done withVRS?

As long as they sell loads of holidays I ain’t too boverrd!!

But the market not showing any enthusiasm for the presentation. Many investors brought in the Covid times and have seen 90% of their investment disappear so AH will need a significant earnings improvement to get the market capitalisation back to those levels. We live in hope!

End of day trading indicates £3m purchase order just gone through. Institutions seeing value and growth prospects we hope!

This share looks decidedly sick! What is going to pull it out of this seemingly terminal decline. No news is making any difference to the company’s prospects as the share price remains unimpressed by anything.

The company are very excited with the news release.

Let’s hope it excites the share price!

Anything to stop this share sinking to oblivion.

We are looking for actual sales revenue and products people are going to buy before the company runs out of money and shareholders run out of patience.

And will this raise AFC profile or add competition to steal the 10 years slog shareholders have suffered?!

Reduction in loss, continued cost savings , sales increasing and product range expanding.

If you have faith in the UK not going belly up this company with good ethics and a strong customer focus has potential to grow for the benefit of shareholders and employees.

These results plus the confirmation of even better to come in second half suggests £6.50 is very fair value!

With increased defence spending in UK and EU plus USA developments we are in an attractive sector.

Hopefully the presentations today will amplify that.

7 million shares sold . If the company goes under does the govt or other organisations have a call on any remaining value to repay grants/ loans given in the past as other creditors would?

I very much hope so. It feels almost criminal for the company to be assessed like this in light of the production coming right. Where are the entrepreneur investors??

With a heavy weight partner they may be able to put pressure on Quadrise far greater than us long suffering shareholders to get something over the line. I do hope it will be before 2030!!

Let’s hope in the build up to the AGM we will get some proper news on future earnings and profitability to move this innovative company out of the penny stock brigade.

After the half year results in September which showed a reduced loss shares have continued to fall.

Whilst there is revenue and a number of projects with potential I start to feel if investors are loosing interest in the wonder material graphene which has many uses but can’t produce profits! Don’t think this company is a basket case like Versarien but the euphoria days are certainly over.

At least it’s an EU based company and gets some funding support but when is it forecast to turn profitable?

Are we being fattened up for passing the cap round again?

Market cap now £34 m and still no income receipts of substance. Don’t get carried away, we been waiting how many years?!

Thank you for the advice.